Spin-coated surface-eroding implants enable automated multi-pulse drug delivery

Roughly half of all patients with chronic illnesses do not take their medications as prescribed, a failure that contributes to disease progression, avoidable hospitalization, and an estimated 100 to 300 billion dollars in excess healthcare costs in the United States every year. Now, a team of biomedical engineers at the University of Mississippi has unveiled a manufacturing technique that could dramatically improve how medication schedules can be built directly into tiny implants, allowing the devices themselves—rather than patients—to keep track of when the next dose is due. The work, published in the journal Biomedical Microdevices, describes a spin-coating approach for fabricating multilayer, surface-eroding implants that release discrete pulses of drug at precisely programmed intervals, achieving timing fidelity that conventional fabrication methods have been unable to match.

The implant concept rests on an elegant geometric principle. Instead of sealed drug reservoirs that must each be opened by a membrane or electronic trigger, the new devices are built as a vertical stack of alternating layers: thin, drug-loaded active layers interleaved between thicker barrier layers made of a degradable composite. The device is encapsulated in polycaprolactone on every face except one, so erosion advances inward from that exposed surface alone. Each time the eroding front reaches an active layer, a dose is released, meaning that the thickness of each barrier layer effectively encodes the interval until the next release event. The number of pulses is therefore set by the number of stacked layers rather than by bulky reservoir compartments, membranes, or power-hungry electronics, offering a passive and fully biodegradable route to multi-dose therapy.

The barrier material at the heart of the device is cellulose acetate phthalate blended with Pluronic F-127, a composite known as CAPP. Cellulose acetate phthalate has a long pharmaceutical history, and under physiological pH its erosion shifts from diffusion-dominated release to surface-erosion-controlled release, the behavior on which the whole architecture depends. The active layers are made of poly(vinyl alcohol) loaded with a fluorescent tracer that stands in for a therapeutic molecule. What had limited earlier versions of such devices was fabrication: previous constructs were made by solvent casting individual films and manually stacking them, a process that produced inconsistent thickness, partial interlayer mixing, and interfaces too irregular to support reliable timing. The Mississippi team, led by Parker Brewster and corresponding author Thomas Werfel, turned to spin coating, a thin-film deposition technique borrowed from microfabrication in which centrifugal force and solvent evaporation jointly determine the final film thickness as a function of solution viscosity, concentration, and rotational speed.

The precision gains reported are striking. Using a formulation of CAPP dissolved in gamma-valerolactone at 60 percent concentration, the researchers calibrated a spin curve showing that film thickness follows an inverse power-law dependence on rotational speed, spanning roughly 436 micrometers at 750 revolutions per minute down to 92 micrometers at 1,750 revolutions per minute, with a fit quality of R-squared equal to 0.979. When compared against solvent-cast films produced at a matched nominal thickness of 400 micrometers, spin coating reduced batch-to-batch thickness variation from approximately 34 micrometers to just 2 micrometers, a seventeen-fold improvement, and reduced variation within individual films from 43 to 47 micrometers down to 5 to 12 micrometers. Atomic force microscopy revealed that at a 100-micrometer target the deepest surface excursion below the mean plane fell from 146.1 nanometers on cast films to only 4.5 nanometers on spun films, roughly a thirty-two-fold improvement in nanoscale flatness.

Chemical homogeneity improved in parallel. Confocal Raman mapping of the film surfaces, tracking the ratio of the cellulose acetate phthalate carbonyl signal to the Pluronic F-127 signature across a 0.3 by 0.3 millimeter grid, showed that cast films contained dramatic local swings in polymer composition, consistent with phase separation during gravity-driven solvent evaporation. Spun films, homogenized by centrifugal shear during deposition, showed a standard deviation in the peak-height ratio of 0.77 against 2.91 for cast films, a nearly four-fold reduction that was statistically significant. Scanning electron microscopy of three-layer test constructs underscored the point at the structural level: cast films bonded with acetone showed extensive interfacial disruption, folding, and delamination, with layer boundaries that could not be confidently resolved, while spin-coated stacks displayed continuous, well-defined interfaces and an active layer measuring 11 micrometers against a 10-micrometer target. Crucially, the aqueous active layer solution could be spun directly onto the organic-solvent-based barrier layers with no detectable interlayer mixing, which is what makes sequential in-situ stacking possible at all.

The functional demonstration came from two device configurations, designated Q16 and Q72 after the approximate inter-pulse intervals they were built to produce. Tested in phosphate-buffered saline at body temperature, both delivered three discrete, sharply separated release events with fluorescence returning to near-baseline between pulses, indicating that drug diffusion through the degrading barrier layers was effectively suppressed. The Q72 devices, each containing barrier units 2.4 millimeters thick built from twelve sequential depositions, released their pulses at 72, 144, and 216 hours, matching the design target within the sampling resolution. The Q16 devices, with 400-micrometer barriers, fired at 4, 20, and 36 hours, a spacing of roughly 16 hours—reproducible across all six devices per condition but about 33 percent longer than the 12-hour design intent.

That overshoot proved scientifically informative. A proportional error in barrier thickness or assumed erosion rate would have lengthened both devices’ intervals by the same fraction, so it could not explain why the shorter interval missed its target while the longer one matched it. The team’s favored explanation is residual solvent: the Q16 devices were tested before an extended vacuum-drying step was adopted, and solvent retained in the polymer bulk—plasticizing the eroding face and slowing degradation—occupies a proportionally larger fraction of a thin barrier’s erosion time than of a thick one’s. The Q72 devices, prepared after the reduced-pressure drying step was instituted, hit their target, supporting the idea that completeness of solvent removal must be specified alongside layer thickness when translating a target interval into a fabrication recipe.

The broader significance of the work lies in how it positions itself against existing pulsatile delivery technologies. Microfabricated reservoir implants, famously pioneered in the late 1990s and later advanced to first-in-human testing of a wirelessly controlled chip delivering daily doses of an osteoporosis drug, achieve programmable dosing but require a sealed compartment and membrane per dose, with the achievable pulse count scaling with device volume and depending on hardware functioning in the body. Oral pulsatile systems—rupture capsules, osmotic devices, compression-coated tablets—avoid hardware but typically manage only one or two bursts and remain sensitive to gastrointestinal pH, transit time, and hydration. The multilayer surface-eroding stack resolves both constraints in principle: pulse count is set by layer count, timing by barrier thickness, and release by biodegradation alone, with no power source, no actuator, and no need for removal surgery in fully degradable versions. The trade-off, inherent to all passive systems, is that the schedule is fixed at fabrication and cannot be revised after implantation.

The timing precision on display also has physiological rationale beyond simple adherence. Many of the body’s own signaling molecules, including insulin, cortisol, and growth hormone, are secreted in pulsatile patterns, and continuous receptor activation can drive desensitization that diminishes drug efficacy over time. Diseases themselves often follow circadian rhythms—asthma attacks, morning blood pressure surges, and arthritis flares all cluster at predictable hours—making chronotherapeutic delivery a genuine clinical goal rather than a laboratory curiosity. An implant whose dosing schedule is baked into its geometry offers a way to align therapy with these rhythms while removing the patient from the equation entirely.

Challenges remain before the technology reaches the clinic. Every barrier deposition in the current process carries a two-hour bake at 90 degrees Celsius, so accumulated thermal history currently restricts the platform to heat-stable pharmaceutical agents, though the authors suggest room-temperature vacuum drying or flash-spinning of thinner layers as routes around this limit. Reaching weekly or monthly dosing windows would require higher volumetric drug density or slower-eroding barrier chemistry rather than simply more thickness. Extending the approach to greater numbers of pulses, substituting real therapeutics for the fluorescent tracer, and validating the devices in vivo are the remaining steps. The principles demonstrated may also extend beyond cellulose acetate phthalate to other surface-eroding polymers such as polyanhydrides, potentially enabling smaller form factors and higher pulse capacity while preserving temporal precision.

For now, the study stands as a compelling demonstration that the humble spin coater—an instrument found in nearly every microfabrication lab—can do more than pattern silicon. Applied to pharmaceutical polymers, it can place degradable barriers and drug layers at specified thicknesses with defined interfaces, repeatably, in a single sequential process, and turn those dimensions directly into a dosing calendar. As healthcare systems grapple with the enormous cost of missed medications, implants that encode a treatment schedule in their own architecture offer an attractive vision of consistent, patient-independent dosing, and this fabrication breakthrough brings that vision measurably closer.